NEWS

5 key takeaways from World Orphan Drug Congress USA Cromos Pharma’s US BDD Nicole Brenna attended World Orphan Drug Congress USA (August 25-27, 2021) in Maryland. It was Cromos Pharma’s first in-person conference since the outbreak of the COVID-19 pandemic. Read Nicole’s 5 key takeaways from the event. The World Orphan Drug Congress USA (WODCUS) took place over two days in Maryland (August 25-27,

Cromos Pharma’s Patient Portal now available in multiple languages

Getting ready for full implementation of the EU Clinical Trial Regulation

Cromos Pharma on rare disease drug development An estimated 475 million people are affected by rare disease worldwide (WEFORUM), and only 5% of people with a rare disease have a treatment. This represents a significant unmet medical need. Rare disease clinical trials involve challenges above and beyond those encountered for large scale clinical studies for more common diseases. Operational and scientific challenges include: Limited pool

Cromos Pharma committed to patient centricity in clinical trials Over the last few years, patient centricity has moved from buzzword to an imperative. Sponsors are now increasingly willing to offer a patient centric approach to studies. However, there remains some confusion over what this means and how to implement it. In this article Cromos Pharma looks at some of the strategies that can be

Cromos Pharma supporting psoriasis clinical research breakthroughs